Rubedo Life Sciences
CompanyUnited States
Rubedo Life Sciences develops 4 assets, the furthest in phase 2 (RLS-1496 in actinic keratosis). Mostly small molecule acting on GPX4, ferroptosis and cellular senescence; based in the United States.
- 4
- Assets
- Furthest stage
- Phase 2
- Raised
- US$52m
- 0
- Trials
- 1
- Signal
Pipeline
4Targets GPX4 to induce ferroptosis in senescent cells.
Phase 2, Small molecule, GPX4, Ferroptosis, actinic keratosis, hair loss
Stage not known
Stage not known
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Funding rounds and grants2
- People24
- Signals1
- Similar companies6